Guru Muralimohan

Entrepreneur-in-Residence

Dr. Guru Muralimohan is a dynamic and decisive leader with a PhD in Immunology and extensive commercial experience in global strategic marketing, new product planning, business development & licensing, and market access within oncology, immunology, cardiovascular and rare disease therapeutic areas.

He is currently Executive Director at Bayer Pharmaceuticals for Oncology Early Pipeline Commercialization team. In addition to his portfolio responsibilities, has is also the commercial lead for BD&L efforts and collaborates effectively with Research, Early Clinical Development, Regulatory, Marketing and Market Access on several cross-functional initiatives.

Prior to Bayer, Guru spent nine years at Boehringer Ingelheim where he worked in US and Global Marketing, US Market Access, and US Strategy & Operations roles. He also has management consulting experience where he led several projects for pharmaceutical, biotech and private equity companies on venture investing, new product planning, search & evaluation and business development & licensing.

Guru started his career at Xcellerex Inc, a Boston based biotech backed by venture capital firms Kleiner Perkins and VantagePoint. In that role he made significant contributions to increase shareholder value eventually leading to acquisition by GE Healthcare.

Guru graduated with a PhD in Immunology from Dr. Anthony Vella’s lab at the University of Connecticut Health Center. He also holds an MBA from University of Connecticut, School of Business.